Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) is a commercial-stage biopharmaceutical company developing and commercializing medicines for rare diseases, with a focus on hematology and cellular metabolism. Its approved medicine mitapivat is sold as PYRUKYND® for hemolytic anemia in adults with pyruvate kinase deficiency… From the company’s description.
Over the twelve months to Sep 30, 2026, Agios Pharmaceuticals, Inc. reported revenue of $140.84M, up 214.4% from a year earlier, and a net loss of $372.90M. Its operating margin was −297.7%, and operations used $331.68M in cash. In fiscal 2025, it reported revenue of $54.03M, up 48.0% from fiscal 2024, and a net loss of $412.78M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Agios Pharmaceuticals, Inc. does
In the company’s own words
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) is a commercial-stage biopharmaceutical company developing and commercializing medicines for rare diseases, with a focus on hematology and cellular metabolism. Its approved medicine mitapivat is sold as PYRUKYND® for hemolytic anemia in adults with pyruvate kinase deficiency and as AQVESME™ for anemia in adults with alpha- or beta-thalassemia in the United States; PYRUKYND® is also authorized for thalassemia in Saudi Arabia. The company is developing mitapivat for additional conditions, including sickle cell disease and pediatric pyruvate kinase deficiency, and its pipeline includes tebapivat, a pyruvate kinase activator being studied for lower-risk myelodysplastic syndromes and sickle cell disease; AG-181 for phenylketonuria; and AG-236, an siRNA targeting TMPRSS6, for polycythemia vera. Agios commercializes its U.S. products directly and works with distribution partners in other markets. In 2021, it sold its oncology business, including vorasidenib, to Servier, and later sold related royalty rights to Royalty Pharma.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1439222
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Agios Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Agios Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Agios Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Agios Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Agios Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”